What is it about?
Discusses the latest developments in the diagnosis and treatment of tuberculosis. Molecular biology has now displaced traditional phenotypic methods for initial diagnosis allowing the identification of Mycobacterium tuberculosis and the mutations associated with resistance to the main drugs (rifampin, isoniazid, fluoroquinolones and second-line injectables) in 24 hours (instead of 4 months). Also, new drugs (bedaquiline, delamanid) and repurposed drugs (linezolid and clofazimine) have been added to increase the probability of attaining a cure for MDR/XDR-TB
Featured Image
Why is it important?
Constitutes a useful review on this topic for those who have to deal with the diagnosis and treatment of these difficult TB cases
Perspectives
After more than 40 years were there were no significant advances in the field, during the last decade there have been incredible developments in the field of drug-resistant tuberculosis, and almost every month we are finding out new diagnostic or therapeutic advances towards the global control of drug-resistant tuberculosis
Rafael Laniado-Laborin
Facultad de Medicina y Psicología, Universidad Autónoma de Baja California
Read the Original
This page is a summary of: Diagnosis and Treatment of Drug-Resistant Tuberculosis: State of the Art, Current Respiratory Medicine Reviews, December 2017, Bentham Science Publishers,
DOI: 10.2174/1573398x13666170926154425.
You can read the full text:
Contributors
The following have contributed to this page
